AbbVie Inc. [NYSE: ABBV] closed the trading session at $107.48 on 09/13/21. The day’s price range saw the stock hit a low of $106.806, while the highest price level was $108.77. The company report on September 13, 2021 that AbbVie and REGENXBIO Announce Eye Care Collaboration.
– AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise.
– Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.
The stocks have a year to date performance of 0.31 percent and weekly performance of -3.71 percent. The stock has been moved at -2.52 percent over the last six months. The stock has performed -7.06 percent around the most recent 30 days and changed -6.86 percent over the most recent 3-months.
If compared to the average trading volume of 6.74M shares, ABBV reached to a volume of 7387063 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AbbVie Inc. [ABBV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $125.96 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 27, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Outperform. The new note on the price target was released on April 07, 2021, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise to $120, while Bernstein analysts kept a Outperform rating on ABBV stock.
The Average True Range (ATR) for AbbVie Inc. is set at 2.59, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 3.55. The Price to Book ratio for the last quarter was 15.12, with the Price to Cash per share for the same quarter was set at 4.84. Price to Free Cash Flow for ABBV in the course of the last twelve months was 17.78 with Quick ratio for the last quarter at 0.80.
ABBV stock trade performance evaluation
AbbVie Inc. [ABBV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.71. With this latest performance, ABBV shares dropped by -7.06% in over the last four-week period, additionally sinking by -2.52% over the last 6 months – not to mention a rise of 19.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 30.98, with the RSI for the last a single of trading hit 26.95, and the three-weeks RSI is set at 34.67 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 116.05, while it was recorded at 108.16 for the last single week of trading, and 110.81 for the last 200 days.
AbbVie Inc. [ABBV]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +34.12 and a Gross Margin at +69.18. AbbVie Inc.’s Net Margin is presently recorded at +9.95.
Return on Total Capital for ABBV is now 19.65, given the latest momentum, and Return on Invested Capital for the company is 6.22. Return on Equity for this stock inclined to 185.81, with Return on Assets sitting at 3.80. When it comes to the capital structure of this company, AbbVie Inc. [ABBV] has a Total Debt to Total Equity ratio set at 665.82. Additionally, ABBV Total Debt to Total Capital is recorded at 86.94, with Total Debt to Total Assets ending up at 57.82. Long-Term Debt to Equity for the company is recorded at 599.46, with the Long-Term Debt to Total Capital now at 78.28.
Reflecting on the efficiency of the workforce at the company, AbbVie Inc. [ABBV] managed to generate an average of $96,936 per employee. Receivables Turnover for the company is 6.43 with a Total Asset Turnover recorded at a value of 0.38.AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.90.
Earnings per share (EPS) analysis for AbbVie Inc. [ABBV] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to 4.68%.
AbbVie Inc. [ABBV]: Insider Ownership positions
There are presently around $127,984 million, or 68.70% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 144,693,566, which is approximately 0.668% of the company’s market cap and around 0.12% of the total institutional ownership; BLACKROCK INC., holding 122,591,994 shares of the stock with an approximate value of $13.18 billion in ABBV stocks shares; and STATE STREET CORP, currently with $8.16 billion in ABBV stock with ownership of nearly 0.619% of the company’s market capitalization.
Positions in AbbVie Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,442 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 51,625,200 shares. Additionally, 986 investors decreased positions by around 49,434,041 shares, while 330 investors held positions by with 1,089,713,600 shares. The mentioned changes placed institutional holdings at 1,190,772,841 shares, according to the latest SEC report filing. ABBV stock had 157 new institutional investments in for a total of 9,196,231 shares, while 68 institutional investors sold positions of 3,685,099 shares during the same period.